*Sponsored by Lifewater Media. Please see disclosures below. |
| iSpecimen (ISPC) Just Released This... |
| | | | | Folks - We have an update about the ticker we sent you originally last night! A potential new catalyst this morning?? Yes.... iSpecimen (ISPC) has just announced a significant enhancement to its searchable inventory, providing researchers with increased access to a broad range of oncology biospecimens that are crucial for cancer research and treatment development. This expanded inventory now includes high-demand cancer samples across various tumor types, stages, and patient demographics—covering colorectal, breast, lung, ovarian, pancreatic, and brain cancers, among others. Researchers can now efficiently find the exact samples they need, facilitating breakthroughs in oncology, personalized medicine, diagnostics, and the development of new therapies. By streamlining access to these samples, they are also shortening sales and fulfillment timelines, which is expected to positively impact revenue growth and profitability. In addition to the expanded inventory, iSpecimen has introduced enhanced lead generation strategies, including email marketing, organic search, and search engine marketing, aimed at increasing inbound order volume. With an estimated $10 million worth of potential orders annually and a targeted 25% conversion rate, this approach aligns with their growth plan, aiming for approximately 20% annual revenue growth. | In other news... iSpecimen (ISPC) formed a strategic partnership this year with an important player in the biotech space. TriMetis Life Sciences is a provider of digital pathology, laboratory, AI workflow and automation solutions. The partnership between iSpecimen and TriMetis aims to revolutionize tissue assessment in preclinical research. By uniting iSpecimen's extensive global network of biospecimen suppliers and researchers with TriMetis' AI-powered, automated digital pathology solutions, this collaboration seeks to tackle industry challenges, minimize the risks tied to manual processes, and transform the landscape of tissue analysis. While there has been no formal update on the details of the partnership in recent months, it may have an impact on ISPC speculators and investors moving forward.
Anyways...
Don't forget to check out our full report from last night! Until Next Time, -Damian |
|
|
|---|
|
*Sponsored by Lifewater Media. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to punjabsvera@gmail.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-two thousand USD by ACH Bank Transfer by Lifewater Media to distribute media via email, SMS, Discord, Facebook, and X/Twitter for iSpecimen Inc. (ISPC) from November 6, 2024 to November 7, 2024. ZipTrader may receive additional campaigns in the future by Lifewater Media to distribute media for iSpecimen Inc. (ISPC). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in iSpecimen Inc. (ISPC). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of iSpecimen Inc. (ISPC), increased trading volume, and possibly an increased share price of iSpecimen Inc. (ISPC), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service.See Our Advertisement/Sponsored Stock Disclaimer. |
| | |
|
|
|---|
|
|
|
